154 related articles for article (PubMed ID: 28624319)
1. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.
Schwartz C; Pfanzelter N; Kuzel TM
Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319
[No Abstract] [Full Text] [Related]
2. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
3. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
Glen H
Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
[TBL] [Abstract][Full Text] [Related]
5. Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.
Tremblay G; McElroy HJ; Westley T; Meier G; Misurski D; Guo M
PLoS One; 2019; 14(3):e0212899. PubMed ID: 30835737
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Grünwald V; Powles T; Choueiri TK; Hutson TE; Porta C; Eto M; Sternberg CN; Rha SY; He CS; Dutcus CE; Smith A; Dutta L; Mody K; Motzer RJ
Future Oncol; 2019 Mar; 15(9):929-941. PubMed ID: 30689402
[TBL] [Abstract][Full Text] [Related]
7. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report.
Zielli T; Gnetti L; Buti S
Tumori; 2020 Dec; 106(6):NP79-NP83. PubMed ID: 32458743
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
9. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
Motzer RJ; Hutson TE; Ren M; Dutcus C; Larkin J
Lancet Oncol; 2016 Jan; 17(1):e4-5. PubMed ID: 26758760
[No Abstract] [Full Text] [Related]
10. Lenvatinib shows promise.
Stone L
Nat Rev Urol; 2015 Dec; 12(12):654. PubMed ID: 26526757
[No Abstract] [Full Text] [Related]
11. Lenvatinib for the treatment of renal cell carcinoma.
Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
[TBL] [Abstract][Full Text] [Related]
12. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Lee CH; Motzer RJ; Glen H; Michaelson MD; Larkin J; Minoshima Y; Kanekiyo M; Ikezawa H; Sachdev P; Dutcus CE; Funahashi Y; Voss MH
Br J Cancer; 2021 Jan; 124(1):237-246. PubMed ID: 33024271
[TBL] [Abstract][Full Text] [Related]
13. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
[TBL] [Abstract][Full Text] [Related]
16. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
Molina AM; Hutson TE; Larkin J; Gold AM; Wood K; Carter D; Motzer R; Michaelson MD
Cancer Chemother Pharmacol; 2014 Jan; 73(1):181-9. PubMed ID: 24190702
[TBL] [Abstract][Full Text] [Related]
18. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
19. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
O'Reilly A; Larkin J
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
